The Medical Minute: What is myelodysplastic syndrome?

June 15, 2012 By Dr. David Claxton

Television journalist and host of "Good Morning America" Robin Roberts announced this week that she has myelodysplastic syndrome, or MDS, an uncommon blood and bone marrow disorder.

MDS is a involving the cells that make up our -- , , and platelets. It is typically a slow-growing type of cancer that affects older people, but it can occur in younger adults and even children.

Certain types of chemotherapy predispose people to MDS, including some common treatments for types of , , and some gastrointestinal malignancies. But many cases of MDS are also found in people who have not been exposed to chemotherapy, so we don’t understand clearly what causes the process.

MDS used to be referred to as “pre-leukemia,” a term doctors don’t use much anymore because although many MDS cases will turn into leukemia, many will not. In some patients with a diagnosis of MDS, the disorder turns into leukemia within just a few months, whereas with others, the condition may remain stable over many years.

The video will load shortly
Watch Dr. Claxton talk more about MDS

There also are a group of disorders that doctors refer to as myeloproliferative disorders, or myeloproliferative syndromes, which has some overlap with MDS. These are different in that the process is more proliferative, seen as increased bone marrow cells in the blood and growth of the spleen. In MDS, however, the blood are usually reduced and, in most cases, the spleen is normal in size.

Symptoms of MDS include weakness, or bleeding or bruising, but there are many other conditions that can also cause those same symptoms. MDS is usually diagnosed after a doctor requests blood work from a patient and blood cell counts -- red cell counts, white cell counts, or platelet counts -- are found to be abnormally low.

In most MDS patients the initial problem is low blood cell counts, specifically red cell counts. Many patients need transfusions over a number of years. Medications also can be effective for some MDS patients. There are two injectable chemotherapies that can sometimes produce complete remission of MDS and, in other cases, offer significant benefit over time. For a selective small group of MDS patients, an oral medication can be very effective. There also are a number of investigational research treatments as part of an active field of study to find a treatment and cure. Today, the only cure for MDS is bone marrow and stem cell transplantation from another individual; for younger patients with MDS this is a particularly good option.

For any given patient with MDS, doctors will examine various factors to determine prognosis. For example, if the changes in the bone marrow suggest a more proliferative or malignant state, that implies increased risk over time for develop of leukemia and death or complications. Chromosome studies are important for understanding risk in MDS, so the bone marrow is examined for changes in chromosomes. MDS patients who develop the disease after are generally at greater risk for problems over time.

In older individuals, MDS and its treatment may affect quality of life but not affect longevity because of other health problems that are more likely to pose a problem before the MDS would become more serious. For younger individuals it is often a serious, life changing and often life-threatening problem.

The limited effective therapies for MDS therefore justify the research efforts underway. Our understanding of MDS is increasing, but better treatments are needed for this difficult problem.

Explore further: Discovery of genetic mutations better diagnose myelodysplastic syndromes

Related Stories

Discovery of genetic mutations better diagnose myelodysplastic syndromes

June 30, 2011
For patients with myelodysplastic syndromes (MDS), choosing the appropriate treatment depends heavily on the prognosis. Those patients at the highest risk of dying from their disease are typically offered the most aggressive ...

Study: Blood cancer may be more common than realized

December 21, 2011
(Medical Xpress) -- A group of life-threatening blood disorders collectively called myelodysplastic syndrome, or MDS, may occur four times more often than reported by national cancer registries, according to new research ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Tom_Hennessy
not rated yet Jun 15, 2012
There is a theory myelodysplasia is a result of increased levels of iron in the body resulting from our high dietary iron , which causes increased red blood cell production. This increased red cell production leads to leukemia.

"Iron chelation and antioxidant therapy may be suitable for the management of MDS".

"Iron Chelation Therapy in Myelodysplastic Syndromes"

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.